Physician profile
Gregory T Czer
NPI 1932218963
$2,007.35
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $142 · 2021: $586 · 2022: $387 · 2024: $21.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $232.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $195.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $190.71 | 2019-2022 | |
| Biotronik INC. | $174.46 | 2019-2021 | |
| Boston Scientific Corporation | $108.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $83.69 | 2019-2021 | |
| Braemar Manufacturing, LLC | $71.65 | 2019 | |
| Pfizer INC. | $70.24 | 2019-2021 | |
| Lilly USA, LLC | $66.66 | 2021-2022 | |
| Amarin Pharma, INC. | $66.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.18 | 2021 | |
| Mylan Specialty L.P. | $55.86 | 2019-2022 | |
| Philips North America LLC | $48.86 | 2019-2022 | |
| Abbott Laboratories | $46.89 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.67 | 2019 | |
| Insulet Corporation | $37.95 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $36.23 | 2019 | |
| Grifols USA, LLC | $28.51 | 2019 | |
| Gilead Sciences, INC. | $23.92 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.36 | 2021 | |
| Amgen INC. | $22.30 | 2019 | |
| Nevro Corp. | $21.34 | 2024 | Senza |
| Medtronic, INC. | $21.25 | 2022 | |
| Novo Nordisk INC | $21.15 | 2021 | |
| Si-Bone, INC. | $18.32 | 2021 | |
| Sanofi Pasteur INC. | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Czer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.